Creating an mRNA vaccine to stimulate immune responses against HIV
Manufacture an mRNA/LNP encoding an HIV envelope designed to bind and stimulate multiple V2 Apex broadly neutralizing antibody B cell lineages
['FUNDING_OTHER'] · DUKE UNIVERSITY · NIH-11078951
This study is testing a new mRNA vaccine that aims to help your immune system fight HIV by training your B cells to produce powerful antibodies, and it's designed for people interested in better ways to protect against the virus.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | DUKE UNIVERSITY (nih funded) |
| Locations | 1 site (DURHAM, UNITED STATES) |
| Trial ID | NIH-11078951 on ClinicalTrials.gov |
What this research studies
This research focuses on developing an mRNA vaccine that encodes a specific HIV envelope protein designed to activate and stimulate the immune system's B cells, which are crucial for producing broadly neutralizing antibodies against HIV. The approach involves manufacturing a messenger RNA (mRNA) that targets naive B cell precursors, aiming to enhance the body's ability to generate a robust immune response against the virus. The vaccine will be tested in preclinical models to evaluate its effectiveness in inducing the desired immune responses.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk for HIV infection who are interested in participating in early-stage vaccine trials.
Not a fit: Patients who are already HIV-positive or those who have a history of severe allergic reactions to vaccine components may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective HIV vaccine that enhances the immune system's ability to fight the virus.
How similar studies have performed: Other research has shown promise in using mRNA technology for vaccine development, particularly in the context of infectious diseases, indicating a potential for success with this novel approach.
Where this research is happening
DURHAM, UNITED STATES
- DUKE UNIVERSITY — DURHAM, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HAYNES, BARTON F. — DUKE UNIVERSITY
- Study coordinator: HAYNES, BARTON F.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus